Ace Therapeutics, a pioneering pre-clinical CROs for stroke, is pleased to announce its rodent stroke behavior testing services. These tests offer scientists valuable measurement methods for evaluating functional recovery and therapeutic efficacy in stroke studies and accelerating the development of novel therapies.
“Our behavioral testing system allows researchers to precisely...
Ace Therapeutics, a leading innovator in preclinical research models, has unveiled a suite of customizable in vivo and in vitro models designed to accelerate Alzheimer’s disease (AD) drug development. With neurodegenerative disorders posing a growing global health challenge, Ace Therapeutics’ advanced platforms provide researchers with highly predictive, translatable tools to...
Ace Therapeutics, a leader in preclinical research solutions, launched its translational imaging solutions specifically designed to accurately characterize Inflammatory Bowel Disease (IBD) animal models. This breakthrough offering empowers researchers with high-resolution, quantitative data to enhance drug development and mechanistic studies.
Imaging techniques play a crucial role in studying...
Ace Therapeutics, a leading preclinical research organization, unveils its specialized nephrology-focused preclinical solutions to accelerate kidney disease drug development. With a comprehensive suite of validated models and cutting-edge technologies, Ace Therapeutics empowers researchers and biopharma companies to overcome challenges in renal drug discovery and translation.
Kidney disease...
Ace Therapeutics announced the launch of its custom ocular modeling services, designed to accelerate advancements in ophthalmology research and enhance the discovery of therapeutic interventions. This groundbreaking service provides researchers with tailored models that closely mimic human ocular conditions, enabling more reliable results in preclinical studies.
As ophthalmological...
Ace Therapeutics, a preclinical CRO in psychiatry dedicated to offering comprehensive one-stop services, released the expansion of its research capabilities in the area of depression through the introduction of comprehensive depression-related behavior tests in its preclinical investigation processes. This integral development aims to enhance the understanding of depressive disorders and...
With a commitment to advancing new drug development for liver and gastrointestinal (GI) diseases, Ace Therapeutics proudly announces the launch of its custom disease model development services, which come with a complete range of research services from target discovery to predictive efficacy testing. This strategic addition to Ace Therapeutics’ portfolio not only enhances its service...
Ace Therapeutics is excited to announce the launch of its groundbreaking glaucoma gene therapy development services. This new initiative is set to advance research in glaucoma treatments, offering comprehensive support and innovation for researchers and pharmaceutical companies aiming to cure this pervasive eye disease.
Glaucoma is a group of eye conditions that damage the optic nerve,...
English
العربية
Français
Español
Português
Deutsch
Nederlands
Italiano
Русский
Română
Português
Ελληνικά
Tiếng Việt